Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diazoxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ11 known ✓ | Q14654 | 3/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | LTK | P29376 | 1/20 | 0.50 |
| ▸ | GRK5 | P34947 | 1/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | PRKX | P51817 | 1/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.50 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.50 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diazoxide SCHEMBL29384603 | 0.98 | CHEK1 (0.51) | CHEK1DAPK3MAP4K4RETPIM1 | |
| Diazoxide SCHEMBL41254 | 0.98 | CHEK1 (0.51) | CHEK1DAPK3MAP4K4RETPIM1 | |
| Diazoxide SCHEMBL1725216 | 0.97 | CHEK1 (0.50) | CHEK1DAPK3MAP4K4RETPIM1 | |
| Diazoxide SCHEMBL1726275 | 0.97 | CHEK1 (0.50) | CHEK1DAPK3MAP4K4RETPIM1 | |
| Diazoxide SCHEMBL28482607 | 0.92 | CHEK1 (0.46) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL10521551 | 0.85 | CHEK1 (0.51) | CHEK1DAPK3MAP4K4RETPIM1 | |
| Diazoxide SCHEMBL225394 | 0.84 | CHEK1 (0.40) | CHEK1DAPK3MAP4K4RETPIM1 | |
| Diazoxide SCHEMBL3920344 | 0.84 | CHEK1 (0.40) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL11694453 | 0.81 | CHEK1 (0.50) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL12570063 | 0.81 | CA2 (0.47) | CHEK1DAPK3MAP4K4RETPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3545958-B1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240207284-A1 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | SOLENO THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-11786536-B2 | Salts of potassium ATP channel openers and uses thereof | ESSENTIALIS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220047605-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| CN-113599386-A | Methods for treating a subject having prader-willi syndrome or smith-magenis syndrome | 伊森舍丽斯有限公司 | 2021-11-05 | — | — | CN | disclosed |
| US-20210322434-A1 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | SOLENO THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| CN-107106500-B | Methods for treating a subject having prader-willi syndrome or smith-magenis syndrome | 伊森舍丽斯有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-11045478-B2 | Salts of potassium ATP channel openers and uses thereof | ESSENTIALIS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10945948-B2 | Compositions and methods for ophthalmic and/or other applications | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-16 | — | — | US | disclosed |
| US-10874676-B2 | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome | Essentials, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20090149451-A1 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090062264-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2009-03-05 | — | — | US | disclosed |
| EP-1968601-A4 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS INC (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2009006483-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1968601-A2 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | Essentialis, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20070191351-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2007-08-16 | — | — | US | disclosed |
| WO-2007081521-A2 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| EP-1781265-A2 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | Essentialis, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006026469-A2 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | ESSENTIALIS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060051418-A1 | Pharmaceutical formulations of potassium ATP channel openers and uses thereof | ESSENTIALIS, INC. | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874676-B2 | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome | KCNJ1, KCNJ11, KCNN1 | KCNJ11 2/4885CHEK1 1183/4885DAPK3 4057/4885 |
| US-20220047605-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | KCNJ11 2/4885CHEK1 3691/4885DAPK3 2386/4885 |
| US-20210322434-A1 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | KCNJ1, KCNJ11, KCNN1 | KCNJ11 2/4885CHEK1 1183/4885DAPK3 4057/4885 |
| US-20070191351-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | KCNJ11 2/4885CHEK1 3691/4885DAPK3 2386/4885 |
| US-20240207284-A1 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | KCNJ1, KCNJ11, KCNN1 | KCNJ11 2/4885CHEK1 1183/4885DAPK3 4057/4885 |
| US-20090062264-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | KCNJ11 2/4885CHEK1 3691/4885DAPK3 2386/4885 |
| US-10945948-B2 | Compositions and methods for ophthalmic and/or other applications | MUC1, PDE6C, STRA6 | KCNJ11 2171/4885CHEK1 3359/4885DAPK3 4795/4885 |
| US-20060051418-A1 | Pharmaceutical formulations of potassium ATP channel openers and uses thereof | KCNJ1, KCNJ11, KCNJ8 | KCNJ11 2/4885CHEK1 3643/4885DAPK3 3836/4885 |
| US-11786536-B2 | Salts of potassium ATP channel openers and uses thereof | KCNJ1, KCNJ11, KCNJ2 | KCNJ11 2/4885CHEK1 3691/4885DAPK3 2386/4885 |
| US-20090149451-A1 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ8 | KCNJ11 2/4885CHEK1 3643/4885DAPK3 3836/4885 |
| US-11045478-B2 | Salts of potassium ATP channel openers and uses thereof | KCNJ1, KCNJ11, KCNJ2 | KCNJ11 2/4885CHEK1 3691/4885DAPK3 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.